Original language | English (US) |
---|---|
Pages (from-to) | 221-224 |
Number of pages | 4 |
Journal | Leukemia and Lymphoma |
Volume | 59 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2 2018 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Leukemia and Lymphoma, Vol. 59, No. 1, 02.01.2018, p. 221-224.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma
AU - Pianko, Matthew J.
AU - Funt, Samuel A.
AU - Page, David B.
AU - Cattry, Deepika
AU - Scott, Emma C.
AU - Ansell, Stephen M.
AU - Borrello, Ivan M.
AU - Gutierrez, Martin
AU - Lendvai, Nikoletta
AU - Hassoun, Hani
AU - Landgren, C. Ola
AU - Lesokhin, Alexander M.
N1 - Funding Information: This work was supported in part by the Memorial Sloan Kettering Cancer Center (MSKCC) NCI core [grant P30 CA008748] (A.M.L.). M.J.P. is supported in part by the MSKCC Mortimer J. Lacher Fellowship supported by the Lymphoma Foundation and also supported in part by a grant from the NIH/National Center for Advancing Translational Sciences (UL1TR00457), administered by the Clinical and Translational Science Center at Weill Cornell Medical Center and MSKCC. A.M.L. is a member of the Parker Institute for Cancer Immunotherapy, which supported the MSKCC Cancer Immunotherapy Program. A.M.L. also receives support from the MSK Sawiris Foundation and Cycle For Survival. We would like to thank the patients and their families for their participation in this clinical study. We would like to thank Katherine Yang and Benedetto Farsaci for providing receptor occupancy data, and Payal Parikh-Patel, Mihaela Popa McKiver and Brian Lestini of Bristol-Myers Squibb for their critical review of the manuscript. Funding Information: This work was supported in part by the Memorial Sloan Kettering Cancer Center (MSKCC) NCI core [grant P30 CA008748] (A.M.L.). M.J.P. is supported in part by the MSKCC Mortimer J. Lacher Fellowship supported by the Lymphoma Foundation and also supported in part by a grant from the NIH/National Center for Advancing Translational Sciences (UL1TR00457), administered by the Clinical and Translational Science Center at Weill Cornell Medical Center and MSKCC. A.M.L. is a member of the Parker Institute for Cancer Immunotherapy, which supported the MSKCC Cancer Immunotherapy Program. A.M.L. also receives support from the MSK Sawiris Foundation and Cycle For Survival.
PY - 2018/1/2
Y1 - 2018/1/2
UR - http://www.scopus.com/inward/record.url?scp=85019717243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019717243&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1320713
DO - 10.1080/10428194.2017.1320713
M3 - Letter
C2 - 28554253
AN - SCOPUS:85019717243
SN - 1042-8194
VL - 59
SP - 221
EP - 224
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -